Axovant Sciences: latest news - GoINPHARMA
Monday, 22 October 2018 - 9:01

Axovant Sciences

Alzheimer’s, Phase III trial of Lundbeck’s candidate fails

Lundbeck has reported the failure of a Phase III trial for its candidate to address Alzheimer’s disease. The drug has not reached, with neither dose, a result different from that obtained through the placebo. Lundbeck has conducted the research in…